Francisco J. Esteva, Chief of Division of Hematology and Medical Oncology at Lenox Hill Hospital, shared on LinkedIn:
“The MammaPrint test, a 70-gene expression assay, is being evaluated for its ability to predict late recurrence risk and the benefit of extended endocrine therapy, EET in early-stage breast cancer patients.
In the IDEAL trial, which studied the duration of extended adjuvant letrozole therapy, Laura van ‘t Veer et al. performed a secondary analysis to see how the MammaPrint test could identify patients who benefit from varying durations of EET.
Among 515 postmenopausal women with hormone receptor-positive early-stage breast cancer, those with low-risk tumors showed significant benefit when treated with 5 years of EET, compared to 2.5 years, in reducing distant recurrence.
For high-risk or ultralow risk tumors, no significant difference was noted between 5 and 2.5 years of EET in reducing distant recurrence.
Takeaway: The MammaPrint assay may guide decisions on the duration of adjuvant endocrine therapy, particularly for patients with low-risk tumors.”
Authors: Laura J. van ’t Veer, Elma Meershoek-Klein Kranenbarg, Marjolijn Duijm-de Carpentier, Cornelis J. H. Van de Velde, Miranda Kleijn, Christa Dreezen, Andrea R. Menicucci, William Audeh, Gerrit-Jan Liefers,
